NBY Stock Analysis: Buy, Sell, or Hold?
NBY - NovaBay Pharmaceuticals, Inc.
$1.95
0.36 (22.64%)
▲
5d:
+27.45%
30d:
+33.56%
90d:
-65.43%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When NBY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NBY shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: NBY shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: NBY is currently trading at $1.95, which is considered fair based on recent price action.
Technical Outlook: Technically, NBY is in a uptrend. The price is approaching resistance at $1.98. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 22.6% recently.
Market Sentiment: NBY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $0.85. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NBY is in a uptrend. The price is approaching resistance at $1.98. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 22.6% recently.
Market Sentiment: NBY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $0.85. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
50/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
76.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: Strong upward momentum (+22.6%)
- BEARISH: Trading 56.4% above Wall St target ($0.85)
Support & Resistance Levels
Support Level
$1.13
Resistance Level
$1.98
Current Trend
Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
42.02
Wall Street Target
$0.85
(-56.4%)
Revenue Growth (YoY)
-78.7%
Share & Embed Analysis
Last updated: June 05, 2026 8:10 AM ET
Data refreshes hourly during market hours. Next update: 9:10 AM
Data refreshes hourly during market hours. Next update: 9:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBY showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$446 | 60 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$82 | 61 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
